Relationship Between the Waiting Times for Surgery and Survival in Patients with Gastric Cancer.


Journal

World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 19 1 2020
medline: 29 12 2020
entrez: 19 1 2020
Statut: ppublish

Résumé

Surgery for gastric cancer should be performed as soon as possible after diagnosis. However, sometimes the waiting time for surgery tends to be longer. The relation between the waiting time for surgery and survival in patients with gastric cancer remains to be fully investigated. This retrospective, single-center cohort study evaluated patients with gastric cancer who underwent curative surgery from 2006 through 2012 at Kanagawa Cancer Center in Japan. Patients who received neoadjuvant chemotherapy were excluded. The waiting time for surgery was defined as the time between the first visit and surgery. We investigated whether the waiting time for surgery has a linear negative impact on outcomes by using a Cox regression model with clinical prognostic factors. In total, 801 patients were eligible. The median waiting time was 45 days (range 10-269 days). The restricted cubic spline regression curve showed that the adjusted time-specific hazard ratios of waiting times did not indicate a linear negative trend on survival between 20 and 100 days (p = 0.759). In the Cox model with a quartile of waiting times, waiting times in the 32-44-day group, 43-62-day group, and ≥63 day groups were not associated with poorer overall survival as compared with the ≤31 day group (HR: 1.01, 95% CI 0.63-1.60, p = 0.984, HR: 1.17, 95% CI 0.70-1.94, p = 0.550, HR: 1.06, 95% CI 0.60-1.88, p = 0.831, respectively). There was no negative relation between the waiting time for surgery (within 100 days) and survival in patients with gastric cancer.

Sections du résumé

BACKGROUND
Surgery for gastric cancer should be performed as soon as possible after diagnosis. However, sometimes the waiting time for surgery tends to be longer. The relation between the waiting time for surgery and survival in patients with gastric cancer remains to be fully investigated.
METHODS
This retrospective, single-center cohort study evaluated patients with gastric cancer who underwent curative surgery from 2006 through 2012 at Kanagawa Cancer Center in Japan. Patients who received neoadjuvant chemotherapy were excluded. The waiting time for surgery was defined as the time between the first visit and surgery. We investigated whether the waiting time for surgery has a linear negative impact on outcomes by using a Cox regression model with clinical prognostic factors.
RESULTS
In total, 801 patients were eligible. The median waiting time was 45 days (range 10-269 days). The restricted cubic spline regression curve showed that the adjusted time-specific hazard ratios of waiting times did not indicate a linear negative trend on survival between 20 and 100 days (p = 0.759). In the Cox model with a quartile of waiting times, waiting times in the 32-44-day group, 43-62-day group, and ≥63 day groups were not associated with poorer overall survival as compared with the ≤31 day group (HR: 1.01, 95% CI 0.63-1.60, p = 0.984, HR: 1.17, 95% CI 0.70-1.94, p = 0.550, HR: 1.06, 95% CI 0.60-1.88, p = 0.831, respectively).
CONCLUSIONS
There was no negative relation between the waiting time for surgery (within 100 days) and survival in patients with gastric cancer.

Identifiants

pubmed: 31953612
doi: 10.1007/s00268-020-05367-8
pii: 10.1007/s00268-020-05367-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1209-1215

Références

Gastric Cancer. 2011 Jun;14(2):113-23
pubmed: 21573742
Ann Surg Oncol. 2017 Jul;24(7):1761-1769
pubmed: 28353020
Br J Cancer. 2015 Mar 31;112 Suppl 1:S92-107
pubmed: 25734382
Can J Surg. 2015 Dec;58(6):414-8
pubmed: 26574834
J Clin Oncol. 2014 Jan 1;32(1):27-33
pubmed: 24276779
JAMA Oncol. 2016 Mar;2(3):330-9
pubmed: 26659430
Ann Surg Oncol. 2016 Aug;23(8):2679-89
pubmed: 27012988
Oral Oncol. 2015 Mar;51(3):272-8
pubmed: 25541458
Gut. 2000 Nov;47(5):618-21
pubmed: 11034575
Gastric Cancer. 2002;5(1):1-5
pubmed: 12021853
Ann Oncol. 2012 Oct;23(10):2731-7
pubmed: 22553194
Eur J Surg Oncol. 2017 Aug;43(8):1447-1455
pubmed: 28528190

Auteurs

Yuta Kumazu (Y)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan.

Koji Oba (K)

Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyoku, Tokyo, 113-0033, Japan.

Tsutomu Hayashi (T)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan. tsuhayas@ncc.go.jp.

Takanobu Yamada (T)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan.

Kentaro Hara (K)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan.

Hiroaki Osakabe (H)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan.

Yota Shimoda (Y)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan.

Masato Nakazono (M)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan.

Shinsuke Nagasawa (S)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan.

Yasushi Rino (Y)

Department of Surgery, Yokohama City University, Yokohama, 3-9 Fukuura, Kanazawaku, Yokohama, Kanagawa, 236-0004, Japan.

Munetaka Masuda (M)

Department of Surgery, Yokohama City University, Yokohama, 3-9 Fukuura, Kanazawaku, Yokohama, Kanagawa, 236-0004, Japan.

Takashi Ogata (T)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan.

Takaki Yoshikawa (T)

Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, 5-1-1 Tsukiji, Chuoku, Tokyo, 104-0045, Japan.

Takashi Oshima (T)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama, Kanagawa, 241-8515, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH